Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Adial Pharmaceuticals announces preclinical data for Purnovate's PNV-5030 » 09:47
10/21/21
10/21
09:47
10/21/21
09:47
ADIL

Adial Pharmaceuticals

$4.15 /

-0.015 (-0.36%)

Adial Pharmaceuticals…

Adial Pharmaceuticals announced data in a pre-clinical model of pain reduction. Based on this positive data, Purnovate, Inc., a wholly owned subsidiary of Adial Pharmaceuticals, Inc., has selected PNV-5030 as the lead compound for its program to develop a drug for the treatment of pain. PNV-5030 has been tested to be more than 1000-fold selective over the adenosine A1 receptor, which is known to have cardiovascular and central nervous system effects across several therapeutic indications. Historically, when selectivity has been achieved over the A1 receptor, water solubility has decreased, making effective tissue distribution in the human body difficult to achieve. However, PNV-5030 has demonstrated solubility more than 50 times greater than other known selective adenosine compounds of the same class. Solubility is often an important characteristic of successful drug candidates, and Purnovate believes solubility is a particularly important characteristic in determining the drug development potential of molecules of this class. In the most recent study, PNV-5030 was tested in a mouse model of somatic nociceptive pain where discomfort was initiated using a laser focused on the mouse's tail, with the time before the mouse flicked its tail away being measured by a sensor. Response groups of 12 mice were analyzed with a control group receiving vehicle alone and other groups receiving either 1mg/kg or 2mg/kg doses of morphine, a common opioid pain relief medication, alone; PNV-5030 alone; or morphine plus PNV-5030. PNV-5030 alone exhibited a significant pain reduction as compared to the control group and a similar effect to 1mg/kg morphine. Importantly, PNV-5030 demonstrated a significant effect when administered with 1 mg/kg morphine as compared to administering 1 mg/kg morphine alone. Interestingly, when combined with 1 mg/kg morphine, PNV-5030 achieved a similar level of pain reduction to the reduction obtained with 2mg/kg morphine. These results could indicate the possibility of lowering the opioid dose to achieve a similar pain reduction level by combining an opioid with PNV-5030 or even eliminating the use of an opioid for pain relief in favor of a higher dose of PNV-5030. Notably, certain mice in both the PNV-5030 plus morphine groups achieved results at the maximum time allowed under the study, and, therefore, may have shown even greater pain reduction results had the protocol allowed continuation of the test beyond the time limit.

ShowHide Related Items >><<
ADIL Adial Pharmaceuticals
$4.15 /

-0.015 (-0.36%)

ADIL Adial Pharmaceuticals
$4.15 /

-0.015 (-0.36%)

10/13/21 Brookline
Brookline starts Adial Pharmaceuticals at Buy with $12 target
10/13/21 Brookline
Adial Pharmaceuticals initiated with a Buy at Brookline
08/26/21 Litchfield Hills
Adial Pharmaceuticals price target raised to $15 from $5 at Litchfield Hills
06/29/21 Litchfield Hills
Adial Pharmaceuticals initiated with a Buy at Litchfield Hills
  • 29
    Jun
ADIL Adial Pharmaceuticals
$4.15 /

-0.015 (-0.36%)

ADIL Adial Pharmaceuticals
$4.15 /

-0.015 (-0.36%)

Over a week ago
Initiation
Brookline starts Adial Pharmaceuticals at Buy with $12 target » 09:34
10/13/21
10/13
09:34
10/13/21
09:34
ADIL

Adial Pharmaceuticals

$3.74 /

+0.01 (+0.27%)

Brookline analyst…

Brookline analyst Kumaraguru Raja initiated coverage of Adial Pharmaceuticals, which is developing AD04 for alcohol use disorder, with a Buy rating and $12 price target. AD04 is in the Phase 3 ONWARD trial with data expected in the first half of 2022 and he expects cash to fund operations into early 2022. Raja sees a favorable risk reward as AD04 and the company's adenosine analogues being developed for a non-opioid pain program advance, the analyst said.

ShowHide Related Items >><<
ADIL Adial Pharmaceuticals
$3.74 /

+0.01 (+0.27%)

ADIL Adial Pharmaceuticals
$3.74 /

+0.01 (+0.27%)

10/13/21 Brookline
Adial Pharmaceuticals initiated with a Buy at Brookline
08/26/21 Litchfield Hills
Adial Pharmaceuticals price target raised to $15 from $5 at Litchfield Hills
06/29/21 Litchfield Hills
Adial Pharmaceuticals initiated with a Buy at Litchfield Hills
  • 29
    Jun
ADIL Adial Pharmaceuticals
$3.74 /

+0.01 (+0.27%)

ADIL Adial Pharmaceuticals
$3.74 /

+0.01 (+0.27%)

Initiation
Adial Pharmaceuticals initiated with a Buy at Brookline » 09:30
10/13/21
10/13
09:30
10/13/21
09:30
ADIL

Adial Pharmaceuticals

$3.74 /

+0.01 (+0.27%)

Brookline analyst…

Brookline analyst Kumaraguru Raja initiated coverage of Adial Pharmaceuticals with a Buy rating and $12 price target.

ShowHide Related Items >><<
ADIL Adial Pharmaceuticals
$3.74 /

+0.01 (+0.27%)

ADIL Adial Pharmaceuticals
$3.74 /

+0.01 (+0.27%)

08/26/21 Litchfield Hills
Adial Pharmaceuticals price target raised to $15 from $5 at Litchfield Hills
06/29/21 Litchfield Hills
Adial Pharmaceuticals initiated with a Buy at Litchfield Hills
  • 29
    Jun
ADIL Adial Pharmaceuticals
$3.74 /

+0.01 (+0.27%)

ADIL Adial Pharmaceuticals
$3.74 /

+0.01 (+0.27%)

Hot Stocks
Adial expects to complete ONWARD Phase 3 trial of AD04 in 1Q22 » 09:30
09/30/21
09/30
09:30
09/30/21
09:30
ADIL

Adial Pharmaceuticals

$4.21 /

-0.115 (-2.66%)

Adial Pharmaceuticals…

Adial Pharmaceuticals announces that greater than 50% of patients expected to complete the ONWARD Phase 3 trial evaluating AD04 as a therapeutic agent for the treatment of Alcohol Use Disorder in persons with certain target genotypes related to the serotonin transporter and receptor genes have completed the full, 24-week, treatment period. ONWARD is a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel group, pivotal Phase 3 clinical trial to evaluate the efficacy, safety and tolerability of AD04 in patients with AUD and selected polymorphisms in the serotonin transporter and receptor genes. The intended primary endpoint for analysis of efficacy is the change from baseline in the monthly number of heavy drinking days during the last 8 weeks of the 24-week treatment period, where heavy drinking is defined as the consumption of 5 or more drinks/day for men and 4 or more drinks/day for women. Drinking levels are self-reported using the timeline follow-back method. The TLFB method is a daily calendar for alcohol consumption and employs memory aids to prompt recall. The TLFB has been used extensively in pharmacotherapy trials for AUD and other substance abuse disorders. Baseline is the 4-week period prior to the screening visit. For each subsequent clinic visit, alcohol consumption is recorded as the number of drinks per day. Patients have been randomized based on a one-to-one ratio, so that approximately 50% of enrolled patients will be in the placebo group and 50% in the AD04 group. Both placebo and active clinical trial material were manufactured in two batches of equal amounts and are light-yellow, oval tablets for oral administration with each tablet weighing approximately 80 mg. Placebo and active tablets are indistinguishable from each other. The active tablets have 0.33 mg of AD04's active ingredient, Ondansetron, in place of a similar volume of excipient in the placebo. They have been packaged in blister-packs of 18 tablets, which allows for 7-days of dosing plus 2-days extra to allow for flexibility in appointment scheduling. During packaging, the clinical trial material was coded so that neither the Company, the doctors, nor the patients can determine whether a package contains placebo or active tablets. Adverse events are monitored by the Company's Chief Medical Officer; Crown CRO, and the trial's Data Monitoring Committee. Clinical trial material can be unblinded in the event one of these safety reviewers determines unblinding is necessary to ensure the safety of any particular trial patient on a case-by case basis. To date, no situations have arisen where it was determined unblinding would be warranted, and therefore, no trial patients have had their dosing unblinded to determine if they were taking placebo or active tablets. ONWARD is being conducted in 25 clinical sites in six countries in Scandinavia and Central and Eastern Europe: Sweden, Finland, Poland, Latvia, Bulgaria and Croatia. The Coordinating Principal Investigator is Professor Hannu E.R. Alho, Emeritus Professor of Addiction Medicine at the University of Helsinki. Patients are genetically screened prior to enrollment in the ONWARD trial so that only genetically positive patients are enrolled. A total of 1216 people were genetically screened with 403 showing genetic positivity for the AD04 target genotypes. Behavioral therapy is administered to all trial patients so that the placebo or drug will be an adjunct therapy to behavioral therapy. This was required by the regulatory authorities because behavioral therapy is considered the standard of care. A successful approval would therefore likely result in a label stating that AD04 should be administered in combination with behavioral therapy. This would be expected to be similar to psychiatric drugs, such as anti-depressants. The Company agreed that use of a standardized counseling protocol in the trial would be important and the Company's Chief Medical Officer provided training for all clinical sites to administer the behavioral therapy. All clinical sites have been certified for using this protocol. In order to qualify for enrollment in ONWARD, in addition to having the genotype, patients had to meet the following additional requirements, among others: Male or female over the age of 18 years old; Qualify as having AUD under the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition; Have experienced 6 or more heavy drinking days in the previous 4 weeks; Have not been abstinent for more than 14 days in the previous 4 weeks; and Expression of a desire to reduce or stop alcohol consumption; Patients meeting the above inclusion criteria were rejected for enrollment in ONWARD based on the following key criteria, among others: Withdrawal symptoms requiring medical intervention at either the screening of baseline visit; Diagnosis of any of the following concomitant psychiatric disorders: non-treated, unstable schizophrenia, bipolar disorder, other psychotic disorder during the lifetime of the patient; Recentdiagnosis of a major depressive disorder, post-traumatic stress disorder, panic disorder or eating disorder; Current or recent treatment with antipsychotics or antidepressants medications, which can have an effect on serotonin receptor or transporter actions, or opiate antagonists, glutamate antagonists, anticonvulsants, serotonin reuptake inhibitors, serotonin antagonists, other antidepressants , dopamine antagonists, and disulfiram; Clinically significant untreated and unstable illness, for example, hepatic or renal insufficiency, or a cardiovascular, pulmonary, gastrointestinal, endocrine, neurological, infectious, neoplastic, or metabolic disturbance; Clinically abnormal ECG or significantly abnormal vital signs; Clinically significant hepatic disease; and; Positive pregnancy test; The ONWARD Phase 3 clinical trial commenced with the opening of a site in Finland in February 2020, and 302 patients have been enrolled. Enrollment was closed on August 30, 2021 immediately after the 302nd patient was randomized for placebo or active treatment and completed the first treatment visit. Since each trial patient undergoes approximately 24 weeks of treatment, the last patient should complete dosing in February 2022. Each patient receives a follow-up call approximately 4 weeks after completing of the full treatment cycle to collect additional safety and tolerability information. As of the week ending September 24th, 120 patients had successfully completed their participation in the trial, 60 patients had discontinued participation in the trial prior to completion, and 122 patients are still being dosed in the trial. As stated above, the last of these patients is expected to complete dosing in February 2022. Patient retention rates continue to exceed projections. As each ONWARD trial site discharges its last patient, the Company will work expeditiously to resolve any outstanding data queries at each site so that it can be closed upon the last follow-up call 4 weeks later. Once the last patient completes his or her final dose, which is expected in February 2022, the Company anticipates closing the last site within 6 weeks. Following closure of the last site, the database containing all the information will be "locked," meaning it can no longer be changed; the trial will be unblinded so that it will be known for each patient whether the patient received placebo or active tablets; and data analysis will commence by the Company's outside statisticians. Results will be released expeditiously, likely within a few weeks of the last site closure.

ShowHide Related Items >><<
ADIL Adial Pharmaceuticals
$4.21 /

-0.115 (-2.66%)

ADIL Adial Pharmaceuticals
$4.21 /

-0.115 (-2.66%)

08/26/21 Litchfield Hills
Adial Pharmaceuticals price target raised to $15 from $5 at Litchfield Hills
06/29/21 Litchfield Hills
Adial Pharmaceuticals initiated with a Buy at Litchfield Hills
  • 29
    Jun
ADIL Adial Pharmaceuticals
$4.21 /

-0.115 (-2.66%)

ADIL Adial Pharmaceuticals
$4.21 /

-0.115 (-2.66%)

Hot Stocks
Adial announces research collaboration agreement with University of Virginia » 09:50
09/28/21
09/28
09:50
09/28/21
09:50
ADIL

Adial Pharmaceuticals

$4.52 /

-0.02 (-0.44%)

Adial Pharmaceuticals…

Adial Pharmaceuticals announced that Purnovate, a wholly owned subsidiary of Adial Pharmaceuticals, has entered into a research agreement with Dr. Mark Roeser from the University of Virginia School of Medicine to develop new formulations of the Company's proprietary adenosine compounds for wound healing through transdermal administration. Under the Agreement, Purnovate will supply certain lead adenosine compounds and Dr. Roeser's research team will be responsible for evaluating these compounds for efficacy and determination of the ideal formulations for maximum absorption with the goal of initiating future clinical trials. The University of Virginia will fund the pre-clinical research activities and the parties will jointly own mutually developed intellectual property. Dr. Roeser is a renowned cardiac surgeon and medical researcher from the University of Virginia School of Medicine. Previously, Dr. Roeser studied how adenosine 2A receptor activation can attenuate tissue damage caused when blood supply returns to tissue after a lack of oxygen. Currently, Dr. Roeser's research is focused on wound healing, specifically for the treatment of burns. Through his research, Dr. Roeser was able to conclude that adenosine 2A receptor agonists can mitigate burn progression through dampening of local inflammatory processes.

ShowHide Related Items >><<
ADIL Adial Pharmaceuticals
$4.52 /

-0.02 (-0.44%)

ADIL Adial Pharmaceuticals
$4.52 /

-0.02 (-0.44%)

08/26/21 Litchfield Hills
Adial Pharmaceuticals price target raised to $15 from $5 at Litchfield Hills
06/29/21 Litchfield Hills
Adial Pharmaceuticals initiated with a Buy at Litchfield Hills
  • 29
    Jun
ADIL Adial Pharmaceuticals
$4.52 /

-0.02 (-0.44%)

ADIL Adial Pharmaceuticals
$4.52 /

-0.02 (-0.44%)

Over a month ago
Options
Sixteen new option listings and three option delistings on September 13th » 08:30
09/13/21
09/13
08:30
09/13/21
08:30
AABA

Altaba

$19.63 /

+ (+0.00%)

, CBB

Cincinnati Bell

$15.48 /

+ (+0.00%)

, ADIL

Adial Pharmaceuticals

$4.13 /

-0.02 (-0.48%)

, ENVB

Enveric Biosciences

$3.44 /

-0.035 (-1.01%)

, PFPT

Proofpoint

$175.92 /

+ (+0.00%)

, ORBC

Taken private

$11.50 /

+ (+0.00%)

, KIN

Kindred Biosciences

$9.25 /

+ (+0.00%)

, USCR

U.S. Concrete

$73.98 /

+ (+0.00%)

, NWHM

New Home Company

$8.99 /

+ (+0.00%)

, QTS

QTS Realty Trust

$77.99 /

+ (+0.00%)

, SYKE

Sykes Enterprises

$53.99 /

+ (+0.00%)

, HTZZ

Hertz

$15.91 /

+0.15 (+0.95%)

New option listings for…

New option listings for September 13th include AABA Stock (AABA), CBB Stock (CBB), Adial Pharmaceuticals Inc (ADIL), Enveric Biosciences Inc (ENVB), CHKAQ Stock (CHKAQ), DOFQW Stock (DOFQW), OASQW Stock (OASQW), PFPT Stock (PFPT), ORBC Stock (ORBC), KIN Stock (KIN), USCR Stock (USCR), IPFF Stock (IPFF), NWHM Stock (NWHM), VALWS Stock (VALWS), QTS Stock (QTS), and SYKE Stock (SYKE). Option delistings effective September 13th include Diamond Offshore Drilling Inc (DOFSQ), Hertz Global Holdings Inc (HTZZ), and Oasis Petroleum Inc (OASPQ).

ShowHide Related Items >><<
USCR U.S. Concrete
$73.98 /

+ (+0.00%)

SYKE Sykes Enterprises
$53.99 /

+ (+0.00%)

QTS QTS Realty Trust
$77.99 /

+ (+0.00%)

PFPT Proofpoint
$175.92 /

+ (+0.00%)

ORBC Taken private
$11.50 /

+ (+0.00%)

NWHM New Home Company
$8.99 /

+ (+0.00%)

KIN Kindred Biosciences
$9.25 /

+ (+0.00%)

HTZZ Hertz
$15.91 /

+0.15 (+0.95%)

ENVB Enveric Biosciences
$3.44 /

-0.035 (-1.01%)

CBB Cincinnati Bell
$15.48 /

+ (+0.00%)

ADIL Adial Pharmaceuticals
$4.13 /

-0.02 (-0.48%)

AABA Altaba
$19.63 /

+ (+0.00%)

CBB Cincinnati Bell
$15.48 /

+ (+0.00%)

ADIL Adial Pharmaceuticals
$4.13 /

-0.02 (-0.48%)

08/26/21 Litchfield Hills
Adial Pharmaceuticals price target raised to $15 from $5 at Litchfield Hills
06/29/21 Litchfield Hills
Adial Pharmaceuticals initiated with a Buy at Litchfield Hills
ENVB Enveric Biosciences
$3.44 /

-0.035 (-1.01%)

07/08/21 Aegis
Enveric Biosciences initiated with a Buy at Aegis
06/28/21 Maxim
Enveric Biosciences initiated with a Buy at Maxim
06/28/21 Maxim
Enveric Biosciences initiated with a Buy at Maxim
PFPT Proofpoint
$175.92 /

+ (+0.00%)

08/02/21 RBC Capital
Mimecast price target raised to $65 from $55 at RBC Capital
07/30/21
Fly Intel: Top five analyst downgrades
07/30/21 JMP Securities
Proofpoint downgraded to Market Perform from Outperform at JMP Securities
05/24/21 Baird
Proofpoint downgraded to Neutral from Outperform at Baird
ORBC Taken private
$11.50 /

+ (+0.00%)

05/11/21 Northland
Orbcomm downgraded to Market Perform from Outperform at Northland
05/10/21 Raymond James
Orbcomm downgraded to Underperform from Strong Buy at Raymond James
04/08/21 Raymond James
Orbcomm can terminate buyout with superior proposal, says Raymond James
04/08/21 Craig-Hallum
Orbcomm downgraded to Hold from Buy at Craig-Hallum
KIN Kindred Biosciences
$9.25 /

+ (+0.00%)

08/23/21 Alliance Global Partners
Kindred downgraded to Neutral from Buy at Alliance Global Partners
06/18/21 Alliance Global Partners
Alliance Global keeps Buy rating on Kindred, thinks another bidder could emerge
06/17/21 Lake Street
Kindred Biosciences downgraded to Hold from Buy at Lake Street
06/17/21 H.C. Wainwright
Kindred Biosciences downgraded to Neutral from Buy at H.C. Wainwright
USCR U.S. Concrete
$73.98 /

+ (+0.00%)

06/15/21 CJS Securities
U.S. Concrete downgraded to Market Perform from Outperform at CJS Securities
06/08/21 DA Davidson
U.S. Concrete price target raised to $74 from $55 at DA Davidson
04/14/21 Truist
U.S. Concrete price target raised to $65 from $35 at Truist
02/25/21 DA Davidson
U.S. Concrete price target raised to $50 from $30 at DA Davidson
NWHM New Home Company
$8.99 /

+ (+0.00%)

QTS QTS Realty Trust
$77.99 /

+ (+0.00%)

06/10/21
Fly Intel: Top five analyst downgrades
06/10/21 Truist
QTS Realty Trust downgraded to Hold from Buy at Truist
06/09/21 Wells Fargo
QTS Realty Trust downgraded to Equal Weight at Wells Fargo
06/09/21 Wells Fargo
QTS Realty Trust downgraded to Equal Weight from Overweight at Wells Fargo
SYKE Sykes Enterprises
$53.99 /

+ (+0.00%)

06/21/21
Fly Intel: Top five analyst downgrades
06/21/21 Barrington
Sykes Enterprises downgraded to Market Perform from Outperform at Barrington
06/21/21 Baird
Sykes Enterprises downgraded to Neutral on takeout at Baird
06/21/21 Baird
Sykes Enterprises downgraded to Neutral from Outperform at Baird
HTZZ Hertz
$15.91 /

+0.15 (+0.95%)

07/07/21 Deutsche Bank
Hertz price target raised to $18 from $2 at Deutsche Bank
USCR U.S. Concrete
$73.98 /

+ (+0.00%)

SYKE Sykes Enterprises
$53.99 /

+ (+0.00%)

QTS QTS Realty Trust
$77.99 /

+ (+0.00%)

PFPT Proofpoint
$175.92 /

+ (+0.00%)

ORBC Taken private
$11.50 /

+ (+0.00%)

KIN Kindred Biosciences
$9.25 /

+ (+0.00%)

HTZZ Hertz
$15.91 /

+0.15 (+0.95%)

  • 29
    Jun
USCR U.S. Concrete
$73.98 /

+ (+0.00%)

PFPT Proofpoint
$175.92 /

+ (+0.00%)

USCR U.S. Concrete
$73.98 /

+ (+0.00%)

SYKE Sykes Enterprises
$53.99 /

+ (+0.00%)

QTS QTS Realty Trust
$77.99 /

+ (+0.00%)

PFPT Proofpoint
$175.92 /

+ (+0.00%)

ORBC Taken private
$11.50 /

+ (+0.00%)

KIN Kindred Biosciences
$9.25 /

+ (+0.00%)

ADIL Adial Pharmaceuticals
$4.13 /

-0.02 (-0.48%)

USCR U.S. Concrete
$73.98 /

+ (+0.00%)

PFPT Proofpoint
$175.92 /

+ (+0.00%)

ORBC Taken private
$11.50 /

+ (+0.00%)

NWHM New Home Company
$8.99 /

+ (+0.00%)

HTZZ Hertz
$15.91 /

+0.15 (+0.95%)

CBB Cincinnati Bell
$15.48 /

+ (+0.00%)

Hot Stocks
Adial Pharmaceuticals exceeds enrollment target in ONWARD Phase 3 trial » 09:33
08/31/21
08/31
09:33
08/31/21
09:33
ADIL

Adial Pharmaceuticals

$4.11 /

-0.08 (-1.91%)

Adial Pharmaceuticals…

Adial Pharmaceuticals announces it has successfully enrolled 302 patients across 25 clinical sites and has now closed enrollment for its ONWARD Phase 3 trial evaluating AD04 as a therapeutic agent for the treatment of Alcohol Use Disorder in persons with certain target genotypes related to the serotonin transporter and receptor genes.

ShowHide Related Items >><<
ADIL Adial Pharmaceuticals
$4.11 /

-0.08 (-1.91%)

ADIL Adial Pharmaceuticals
$4.11 /

-0.08 (-1.91%)

08/26/21 Litchfield Hills
Adial Pharmaceuticals price target raised to $15 from $5 at Litchfield Hills
06/29/21 Litchfield Hills
Adial Pharmaceuticals initiated with a Buy at Litchfield Hills
  • 29
    Jun
ADIL Adial Pharmaceuticals
$4.11 /

-0.08 (-1.91%)

Recommendations
Adial Pharmaceuticals price target raised to $15 from $5 at Litchfield Hills » 14:40
08/26/21
08/26
14:40
08/26/21
14:40
ADIL

Adial Pharmaceuticals

$3.83 /

+0.04 (+1.06%)

Litchfield Hills analyst…

Litchfield Hills analyst Theodore O'Neill raised the firm's price target on Adial Pharmaceuticals to $15 from $5 and keeps a Buy rating on the shares following the company's Q2 earnings results. O'Neill boosted his price target to reflect the potential financial impact of AD04. The analyst estimates the U.S. market for Adial's AD04 for Alcohol Use Disorder, or AUD, could exceed $21B annually by 2025, adding that genetic testing will help boost revenue by separating those who will respond to AD04 from those who won't, which is useful for insurers who will want to confirm before covering treatment.

ShowHide Related Items >><<
ADIL Adial Pharmaceuticals
$3.83 /

+0.04 (+1.06%)

ADIL Adial Pharmaceuticals
$3.83 /

+0.04 (+1.06%)

06/29/21 Litchfield Hills
Adial Pharmaceuticals initiated with a Buy at Litchfield Hills
  • 29
    Jun
ADIL Adial Pharmaceuticals
$3.83 /

+0.04 (+1.06%)

Conference/Events
Adial Pharmaceuticals to host business news update conference call » 10:50
08/20/21
08/20
10:50
08/20/21
10:50
ADIL

Adial Pharmaceuticals

$3.30 /

+0.17 (+5.43%)

Management holds a…

Management holds a business update conference call on August 20 at 11 am. Webcast Link

ShowHide Related Items >><<
ADIL Adial Pharmaceuticals
$3.30 /

+0.17 (+5.43%)

ADIL Adial Pharmaceuticals
$3.30 /

+0.17 (+5.43%)

06/29/21 Litchfield Hills
Adial Pharmaceuticals initiated with a Buy at Litchfield Hills
  • 29
    Jun
ADIL Adial Pharmaceuticals
$3.30 /

+0.17 (+5.43%)

Hot Stocks
Adial Pharmaceuticals reaches full enrollment target for ONWARD Phase 3 trial » 10:47
08/20/21
08/20
10:47
08/20/21
10:47
ADIL

Adial Pharmaceuticals

$3.32 /

+0.19 (+6.07%)

Adial Pharmaceuticals…

Adial Pharmaceuticals announces it has reached its full enrollment target of 290 subjects in the Company's ONWARD Phase 3 trial evaluating AD04 as a therapeutic agent for the treatment of Alcohol Use Disorder in persons with certain target genotypes related to the serotonin transporter and receptor genes. ONWARD trial completion is expected in the first quarter of 2022.

ShowHide Related Items >><<
ADIL Adial Pharmaceuticals
$3.32 /

+0.19 (+6.07%)

ADIL Adial Pharmaceuticals
$3.32 /

+0.19 (+6.07%)

06/29/21 Litchfield Hills
Adial Pharmaceuticals initiated with a Buy at Litchfield Hills
  • 29
    Jun
ADIL Adial Pharmaceuticals
$3.32 /

+0.19 (+6.07%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.